We Analyzed 846 Peptide Clinic Menus and Found the Industry’s Biggest Misconception
Everyone has an opinion about what peptide clinics offer. Almost no one has counted. We reviewed the published treatment menus of 846 verified peptide clinics across all 50 states to answer a simple question with data instead of anecdote. What does peptide medicine in America actually look like, one clinic menu at a time? The answer overturns the most common assumption in the field, one many clinic owners hold about their own industry. The belief is that peptide medicine is a weight loss business. It is not.
Do you run a peptide clinic? HealingMaps has launched the first Group Purchasing Organization for peptide and other independent clinics, and it is free to join. Members get 40%+ off medical supplies, discounted professional medmal and liability insurance created for emerging-treatment practices, LegitScript certification at a huge discount (now required to advertise peptides, GLP-1s, and NAD+), and HIPAA-compliant credit card processing. There is zero cost or obligation to become a member.
Sign Up Here: → healinghealthalliance.com/contact
Key Takeaways
| Key Takeaway | What It Means |
|---|---|
| BPC-157 is the most offered compound | It appears on 55% of clinic menus, ahead of every GLP-1 drug. |
| Recovery outweighs weight loss | 71% of clinics offer a recovery or growth peptide; 47% offer a named GLP-1 drug. |
| Few clinics do both well | Only 35% offer both a recovery peptide and a weight loss drug. |
| The July FDA vote reaches most clinics | 57% offer at least one of the seven compounds under review. |
| Supply is geographically concentrated | California, Florida, and Texas hold the densest clinic clusters. |
The Most Offered Peptides in America
Interested in peptide therapy? Find vetted peptide therapy clinics near you.
The top of the list is a recovery story. BPC-157 leads, followed by the growth hormone peptides sermorelin, ipamorelin, and CJC-1295. Semaglutide, the compound most people associate with the entire category, ranks fifth. The table below shows the ten most offered compounds nationally.
| Rank | Compound | Share of Clinics |
|---|---|---|
| 1 | BPC-157 | 55.3% |
| 2 | Sermorelin | 48.9% |
| 3 | Ipamorelin | 42.9% |
| 4 | CJC-1295 | 41.8% |
| 5 | Semaglutide | 39.2% |
| 6 | TB-500 | 31% |
| 7 | Tirzepatide | 29.1% |
| 8 | GHK-Cu | 28.6% |
| 9 | PT-141 | 27.3% |
| 10 | NAD+ | 23.3% |
Two patterns stand out. First, the growth hormone stack of sermorelin, ipamorelin, and CJC-1295 is nearly ubiquitous, which reflects how central hormone optimization has become to these practices. Second, GHK-Cu and PT-141 both crack the top nine, showing that skin and sexual health are mainstream clinic offerings, not niche add ons.
The Biggest Misconception: That This Is a Weight Loss Industry
The misconception is about identity. The public thinks of peptide clinics as weight loss shops because GLP-1 drugs made the news. The menus say otherwise. In our review, 71% of clinics offer at least one recovery or growth peptide, while 47% offer a named GLP-1 weight loss drug. Only 35% offer both.
That split has strategic weight for operators. A clinic built entirely around compounded GLP-1 drugs is exposed to both FDA enforcement and the coming branded price cuts. A clinic anchored in recovery and hormone optimization sits on a more durable base. The market, measured menu by menu, has already tilted toward the second model.
Why the July FDA Vote Reaches Most of the Industry
On July 23 and 24, the Pharmacy Compounding Advisory Committee reviews seven peptides for the 503A bulks list. That meeting is not a niche event. In our data, 57% of clinics offer at least one of the seven compounds under review, which means the vote touches the majority of the industry directly.
Exposure is uneven across the seven. BPC-157 and TB-500 are widely offered, so a decision on those two moves the most menus. DSIP and KPV appear far less often, so their fate affects a smaller slice. The table below shows how often each compound under review appears across our verified clinics.
| Compound Under FDA Review | Share of Clinics Offering It |
|---|---|
| BPC-157 | 55.3% |
| TB-500 | 31% |
| MOTS-c | 15.1% |
| Semax | 13.8% |
| Epitalon | 12.4% |
| KPV | 6.5% |
| DSIP | 5.4% |
The concentration at the top of that table explains why the industry is watching BPC-157 so closely. It is not only the most offered compound overall. It is also the one on the July agenda with the widest reach into real clinic menus. The full regulatory context sits in our breakdown of the 503A bulks list review.
Where Peptide Medicine Concentrates
Clinic supply is not spread evenly across the map. California leads with 84 verified clinics, followed by Florida with 72 and Texas with 70. After the big three, the distribution flattens quickly, with Ohio, New York, Washington, and Illinois forming a second tier in the high twenties to low thirties.
For operators, geography is competitive intelligence. A dense market like South Florida rewards depth of menu and clear differentiation, because patients can comparison shop. A thinner market rewards being the credible local option before a national franchise arrives. Our directories map that supply in detail, from the BPC-157 clinic map to the broader peptide clinic directory.
What the Data Says to a Clinic Owner
Three practical readings follow from these numbers. First, if your practice is GLP-1 heavy, you are exposed on two fronts and undersized on the recovery menu that most of your peers offer. Second, if you do not carry the growth hormone stack, you are missing the most common offering in the country. Third, the July vote deserves your attention even if you think of yourself as a weight loss clinic, because most clinics touch it somewhere.
None of this argues that every clinic should offer every compound. It argues for knowing where you sit relative to the market before the regulatory ground shifts. Menu strategy is easier to fix in June than in a scramble after a July vote.
The Bottom Line
Peptide medicine in America is a recovery and hormone optimization field with a large weight loss wing, not the other way around. BPC-157 leads the national menu, most clinics are exposed to the July FDA vote, and supply concentrates in a handful of large states. The clinics that read the map clearly, and diversify beyond the headline compounds, are the ones built to last. For a foundation on the therapy itself, see what peptide therapy is and how it works.
